Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 225 a 250 de 345
Resumen de: EP3415909A1
0001 The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
Resumen de: WO2025169282A1
Provided are a method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases, and a method for discriminating atopic dermatitis and other skin diseases using said protein marker. More specifically, the method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases includes collecting, from a sample collected from the skin of a subject, at least one protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2, and PRG2.
Resumen de: US2022034912A1
The present invention refers to p53 sequence and post translational modifications (PTMs) and to their use as biomarkers in the diagnosis of neurodegenerative disease and cognitive decline and/or in the prognosis of Alzheimer's disease at different stages and/or of neurodegenerative disease in a biological sample. The invention also provides for a 1) diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of neurodegenerative disease, including Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), fronto-temporal dementia (FTD), Lewi's Body (LB), and vascular dementia (VD) in a subject, by evaluating the PTMs to the said p53 linear sequence protein and possible cut of its full sequence specifically in human plasma of patients; and 2) prognosis of AD in CU and MCI patients.
Resumen de: KR20260133425A
본 발명은 D-아미노산 대사 효소인 세린 라세메이스(Serine racemase, SR) 및 D-아미노산 산화효소(D-Amino acid oxidase, DAAO)를 이용한 신경 퇴행성 뇌질환 진단 방법에 관한 것으로, 알츠하이머병(AD) 및 파킨슨병(PD) 환자의 혈장 샘플에서 SR 및 DAAO의 활성이 건강한 사람(HC) 대비 현저히 증가함을 확인하였으며, 이를 신경 퇴행성 질환의 바이오마커로 활용할 수 있음을 제시한다. 특히, 본 방법은 혈액 샘플을 이용하는 비침습적 방식으로, 기존의 고가이며 절차가 복잡한 영상 진단법 및 침습적 검사법의 한계를 극복하여 신경 퇴행성 뇌질환을 보다 신속하고 경제적으로 진단할 수 있으며, 치료제 스크리닝에 활용하여 우수한 효과를 갖는 신약 개발에 기여할 수 있다.
Resumen de: CN122690124A
0001 本发明公开了一种基于Si@Ag/Pt纳米酶的双模态检测Aβ<40>寡聚体的试剂盒、方法、系统及其应用。本发明所述试剂盒包括：包被有捕获抗体的固相载体，所述捕获抗体能够与待测样本中的Aβ<40>寡聚体特异性结合；检测探针，所述检测探针为Aβ<40>寡聚体特异性识别分子修饰的Si@Ag/Pt纳米酶探针，对待测样本中的Aβ<40>寡聚体进行捕获与信号转导；任选地，包括用于比色检测的显色底物。本发明将Aβ<40>寡聚体特异性识别分子修饰的Si@Ag/Pt纳米酶探针应用于夹心免疫分析中，利用同一探针兼具的强光散射特性和高效类过氧化物酶活性，在同一检测体系中实现对目标物的明场成像颗粒计数与催化比色双模式信号输出。两种模式独立定量、结果互验，极大地提升了检测的可靠性。
Resumen de: CN122690133A
0001 本发明提供了镁离子在缓解冻存样本检测偏差中的应用，涉及免疫检测领域。本发明通过添加镁离子有效缓解了化学发光免疫分析法检测过程中冻存样本与非冻存样本的检测偏差，提高了临床检测的准确性和可靠性。
Resumen de: WO2025169281A1
Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker. More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.
Resumen de: US20260258495A1
The present invention relates to a biomarker for the early diagnosis of Alzheimer's disease and a use thereof, and more particularly, the present invention relates to: a biomarker composition for the early diagnosis of Alzheimer's disease, the biomarker composition comprising one or more genes selected from the group consisting of alpha-2-macroglobulin (A2M), creatine kinase M-type (CKM), filamin-A (FLNA), integral alpha-IIb (ITGA2B), alpha-1-acid glycoprotein 2 (ORM2), phospholipid transfer protein (PLTP), haptoglobin (HP), sulfhydryl oxidase 1 (QSOX1), protein-glutamine gamma-glutamyltransferase 2 (TGM2), filamin C (FLNC), heat shock protein 70 (HSP70) and lysomal alpha-mannosidase (MAN2B1), or a protein expressed from the genes; a method for the early diagnosis of Alzheimer's disease; a diagnostic kit for the early diagnosis of Alzheimer's disease; and a method for providing information for predicting and diagnosing Alzheimer's disease.
Resumen de: US20260256717A1
In alternative embodiments, provided are drugs and companion diagnostics, or therapeutic drug combinations and a companion diagnostic comprising a dried blood spot or a volumetric dried blood spot, or an at-home high-volume liquid blood, collection device, including products of manufacture and kits, and methods, for using them. In alternative embodiments, provided are novel methods for dosaging therapeutic drug compositions. In alternative embodiments, provided are artificial intelligence (AI)-enabled therapeutic drug compositions (bMEDs™), including bMEDs™ amifampridine for Lambert Eaton Myasthenic Syndrome (LEMS), bMEDs™ deflazacort to Duchenne Muscular Dystrophy (DMD), bMEDs™ propranolol for Infantile Hemangioma, bMEDs™ serabelisib for PIK3CA-Related Overgrowth Spectrum (PROS), bMEDs™ sirolimus for Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon (“KHE w/KMP”), bMED™ everolimus for TSC-associated epilepsy, TSC-associated SEGA, TSC-associated renal angiomyolipoma, breast cancer, pNET, renal cancer, or allograph organ rejection prophylaxis, and bMEDs™ for rare diseases as provided herein.
Resumen de: US20260258105A1
0000 The disclosure relates to the engineering of IL-35 cytokine polypeptides to achieve improved therapies for inflammatory diseases and conditions. Accordingly, aspects of the disclosure relate to a polypeptide comprising SEQ ID NO:2, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:2, wherein the one or more amino acid substitutions comprise K23, R74, R195, R197, or combinations thereof. Further aspects relate to a polypeptide comprising SEQ ID NO:4, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:4, wherein the one or more amino acid substitutions comprise C74. Further aspects relate to a polypeptide comprising SEQ ID NO:6, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:6, wherein the one or more amino acid substitutions comprise C34.
Resumen de: US20260259227A1
0000 Provided herein are methods for determining whether a disorder is susceptible to treatment with a plasma kallikrein inhibitor and methods for identifying a subject as a candidate for treatment with a plasma kallikrein inhibitor. Provided herein are methods of identifying a subject as having or being at risk for a disorder and methods of treating a disorder in a subject. Also provided herein are methods of evaluating effectiveness of a treatment in a subject.
Resumen de: US20260258472A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Resumen de: US20260259229A1
A common molecular signature of elevated oxidative stress is detected in blood samples from individuals with fatigue syndromes, including LC, ME-CFS, and lupus patients reporting fatigue. Analysis can be performed with one or more of flow cytometry, bulk RNA-seq analysis, mass spectrometry, and systems chemistry analysis. Elevated reactive oxygen species (ROS) were found, as well as differences in glutathione ROS clearance pathways and markers of oxidative damage.
Resumen de: US20260258354A1
The present invention relates to a method for generating a microglia-sufficient brain organoid comprising the step of incubating primitive-like macrophage cells with a brain organoid that is between about 15 to about 30 days old in cerebral organoid medium comprising CSF-1 in a low attachment cell culture vessel to generate microglia cells. The present invention also relates to a microglia-sufficient brain organoid obtained by the method as described herein.
Resumen de: WO2025179269A1
The disclosure provides a therapeutic composition comprising pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells (hucMSCs) derived from at least four and up to twelve donors, which can be reproduced with batch to batch consistency. These cells exhibit consistent marker expression profiles, enhanced and consistent secretion of therapeutic factors, and potent immunomodulatory activities after at least ten to thirty population doublings. The composition, formulated with a pharmaceutically acceptable carrier, is designed for clinical applications addressing inflammatory, immune, and degenerative conditions.
Resumen de: WO2025179149A1
Provided herein are methods and systems for diagnosing pathological conditions using machine learning and artificial intelligence models. An exemplary method can include loading an abundance matrix that represents mass spectrometry reads of a sample of a plurality of volatile organic compounds (VOCs) extracted from a biological sample. The abundance matrix can represent each of the plurality of VOCs in a mass-to-charge ratio dimension, an abundance dimension, and a retention time dimension. The method can include providing the abundance matrix to a machine-learning model. The machine- learning model can be trained on abundance matrixes of biomarkers of VOCs collected from healthy and diseased subjects. The method can include receiving, from the machine-learning model, a prediction of a state of a disease state.
Resumen de: US20260259201A1
Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the editing, detecting and/or engineering of nucleic acids.
Resumen de: US20260259219A1
Provided is a method for measuring proteomic cysteine redox status in a sample obtained from a bodily fluid of a subject, the method comprising: (i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form; (ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins; (iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols; (iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry, (v) processing the sample for analysis by mass spectrometry; and (vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample. The invention also provides related methods for biomarker discovery and for predicting presence of a liver disease and/or cancer, such as hepatocellular carcinoma (HCC) in a subject.
Resumen de: WO2026183546A1
A three-dimensional (3D) bioprinted model of a forebrain cortex is designed to quantify neurite outgrowth across a hydrogel bridge. The 3D bioprinted model includes two cell-laden compartments formed using a first hydrogel matrix, separated by a hydrogel bridge formed from a second, stiffer hydrogel matrix. The model may fit within standard 96-well plate formats, enabling medium-throughput screening applications. The model was validated using Alzheimer's disease forebrain cortical populations, demonstrating significant reductions in neurite outgrowth from Alzheimer's disease populations compared to controls.
Resumen de: WO2026181008A1
The invention provides methods of assessing abundance of GABAergic somatostatin positive interneurons (SST+ cells) in living brain tissue of a subject by calculating a polygenic risk score using genomic variants of genes co-expressed with SST mRNA and their cis expression quantitative trait loci (cis-eQTLs); or where the genomic variants associated with SST+ cell abundance are variants directly associated with inter-individual variability in SST cell type proportions estimated from bulk RNA-seq data. Also provided are related diagnostic methods.
Resumen de: WO2026183240A1
The presently described and claimed technology relates to high-throughput automated methods for detecting brain derived tau (BD-tau) in a biological sample using an immunoassay analyzer.
Resumen de: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
Resumen de: WO2026183319A1
Described herein are methods of identifying cell-type specific proteins that are transmembrane on or internal to extracellular vesicles (EVs).
Resumen de: US20260258118A1
0000 The present invention relates to a method for detecting markers of fibroblast activation in a patient by sandwich immunoassay to identify patients, particularly cancer patients who would benefit from anti-TGFβI therapy. The markers of fibroblast activation may be selected from the N-terminal pro-peptide of Collagen III (Pro-C3), the N-terminal pro-peptide of Collagen VI (Pro-C6), the N-terminal pro-peptide of Collagen I (Pro-C1) and/or an internal sequence in the N-terminal region of type 3 collagen (P3NP). The invention also provides an anti-TGFβI therapy for use in the treatment of cancer and/or fibrosis.
Nº publicación: US20260256858A1 03/09/2026
Solicitante:
PSYCHED WELLNESS LTD [CA]
Psyched Wellness Ltd.
Resumen de: US20260256858A1
0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.
BOPI
Sede Electrónica
